Actavis produces and markets generic pharmaceutical products, covering most significant therapeutic categories.

The Group packages and sells a number of these products under its own–label names. Delivering a fully integrated management team that shares a common strategy and philosophy, the Company has 4 Sales and Marketing divisions for own-label products, representing different geographical areas.

The Group’s biggest “own-label” markets are the US, Turkey, Bulgaria, Russia and the CIS, Germany, UK, the Nordic countries and Serbia. 

Actavis’ broad product portfolio of over 830 products encompasses all of the major therapeutic areas and formulations. In addition to tablets and capsules, Actavis sells injectables, suspensions, infusions, suppositories, gels, syrups, creams and ointments.

Robust registration of Actavis’ products to new markets provides our customers with a broad range of generic products.

Wholesalers, pharmacies, medical practitioners, health authorities and other pharmaceutical manufacturers are among the diverse customers served by Actavis.

The Group’s operations are geared towards providing our customers with the highest possible level of service. Quality products, fast and reliable service as well as first-class working practices are the key to winning future business and retaining customer loyalty.

Third-party sales
Actavis' sales of intellectual property and product sales to clients who then sell the products under their own-labels is handled by the Company’s subsidiary Medis.

Medis has established itself as a reliable source of pharmaceutical intellectual property.

• 
• 
•